Skip to main content
Aarti Pharmalabs Limited logo

Aarti Pharmalabs Limited — Investor Relations & Filings

Ticker · AARTIPHARM ISIN · INE0LRU01027 LEI · 335800TTAKRBNDK5P363 BSE.NS Manufacturing
Open in API
Filings indexed 246 across all filing types
Latest filing 2026-01-29 Regulatory Filings
Country IN India
Listing BSE.NS AARTIPHARM

About Aarti Pharmalabs Limited

https://www.aartipharmalabs.com/

Aarti Pharmalabs Limited is a manufacturer of Active Pharmaceutical Ingredients (APIs), pharmaceutical intermediates, and xanthine derivatives. The company specializes in the development and production of complex chemistry-based products for the global pharmaceutical and generic drug industries. Its core portfolio includes APIs across diverse therapeutic areas such as oncology, cardiovascular, and anti-diabetics. Additionally, the company is a major producer of xanthines, including caffeine and theophylline. Aarti Pharmalabs offers comprehensive Contract Development and Manufacturing Organization (CDMO) services, leveraging its integrated research and development capabilities and large-scale manufacturing facilities. The organization maintains high regulatory standards, ensuring compliance with international quality benchmarks to serve a global clientele.

Recent filings

Filing Released Lang Actions
Board Meeting — Financial Results/Dividend
Regulatory Filings Classification · 95% confidence The document is a formal notice addressed to stock exchanges regarding an upcoming Board Meeting scheduled for February 9, 2026. The purpose of the meeting is to consider and approve the unaudited financial results for the quarter ended December 31, 2025, and to declare an interim dividend if any. The document references Regulation 29 of SEBI Listing Obligations and Disclosure Requirements, which mandates disclosure of such board meeting notices. The document does not contain the financial results themselves, only an intimation of the meeting where these results will be approved and announced. The document length is short (1796 characters) and it serves as a notification rather than a report. Therefore, it is best classified as a Regulatory Filing (RNS) since it is a regulatory announcement about an upcoming event and not the actual financial report or dividend declaration.
2026-01-29 English
Spurt in Volume
Regulatory Filings Classification · 95% confidence The document is a letter addressed to the National Stock Exchange of India Limited, responding to a query about an increase in trading volume of the company's securities. It clarifies that no undisclosed information or announcements exist that could affect the stock price or volume, and that the volume increase is market-driven. There is no financial data, report, or detailed disclosure here, only a regulatory clarification letter. The document length is short (1585 characters), and it is a regulatory communication responding to an exchange query. This fits best under Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and compliance communications that do not fit other categories.
2026-01-12 English
Certificate under SEBI (Depositories and Participants) Regulations, 2018
Regulatory Filings Classification · 95% confidence The document is a certificate issued under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming dematerialisation activities for the quarter ended December 31, 2025. It is addressed to stock exchanges and compliance departments, and it is a compliance certificate rather than a financial report or announcement of financial results. The document length is short (3150 characters) and it is a regulatory compliance certificate related to securities dematerialisation, not a report or announcement of voting results, management changes, or financial performance. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory compliance documents that do not fit other specific categories.
2026-01-06 English
Change in Management
Board/Management Information Classification · 100% confidence The document is a formal notification addressed to stock exchanges (BSE and NSE) regarding the appointment of a senior management personnel, Dr. Rakeshwar Bandichhor, as Chief Scientific Officer – R&D. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, specifically Regulation 30, which pertains to disclosures about changes in senior management. The content includes details about the appointment date, the individual's profile, and the regulatory basis for the disclosure. There is no financial data, earnings information, or report publication mentioned. The document is clearly an announcement of a management change rather than a full report or other filing type.
2026-01-01 English
Trading Window
Regulatory Filings Classification · 95% confidence The document is a letter addressed to stock exchanges regarding the closure of the trading window pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015. It announces the trading window closure period related to the upcoming financial results for the quarter ending December 31, 2025. The document does not contain any financial data or results itself, nor does it include a report or detailed financial information. It is a regulatory announcement related to insider trading compliance and timing of financial results disclosure. The document length is short (1522 characters), and it is clearly an announcement rather than a report. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2025-12-22 English
Analysts/Institutional Investor Meet/Con. Call Updates
Call Transcript Classification · 100% confidence The document is a transcript of the Q2 FY26 earnings conference call of Aarti Pharmalabs Limited held on November 11, 2025. It includes detailed discussions of financial results, business segments, operational updates, and a Q&A session with analysts. The text explicitly mentions it is a transcript of the earnings call, which is a full text record of the conference call including management remarks and Q&A. This matches the definition of a Call Transcript (CT). The document is lengthy (15,000 characters) and contains substantive financial data and management commentary, confirming it is not just an announcement or summary. Therefore, the appropriate classification is Call Transcript (CT).
2025-11-17 English

Browse filings by year

4 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.